For a patient sitting in a cardiologist's office with chest pain, the diagnostic path has long been binary. They can undergo a non-invasive scan that shows anatomy but not function, or they can proceed directly to an invasive angiogram, a catheter-based procedure that carries its own small but real risks. The promise of fractional flow reserve derived from CT scans (FFR-CT) is to collapse that choice, offering a detailed, functional assessment of coronary blockages from a standard scan alone. In Wroclaw, Poland, a team of over a hundred bioengineers and clinicians at Hemolens has spent nearly a decade refining its own take on that promise, building the Cardiolens FFR-CT Pro platform. The company is now in the critical phase of clinical validation, aiming to prove its software can accurately and safely guide treatment for the millions globally diagnosed with chronic coronary syndromes [Hemolens, retrieved 2026].
The computational fluid dynamics wedge
Hemolens's technology, like that of market leader HeartFlow, is built on a foundation of computational fluid dynamics (CFD). The software takes data from a coronary CT angiography (CCTA) scan and, by applying the laws of physics to model blood flow, calculates virtual FFR values. These numbers estimate the pressure drop across a stenosis, indicating whether a blockage is likely to be flow-limiting and require intervention. Where Hemolens seeks differentiation is in its algorithmic approach and its integration of continuous non-invasive blood pressure (CNBP) data, which it claims allows for a more personalized hemodynamic assessment [Hemolens, retrieved 2026]. The core bet is that its proprietary CFD models, developed by pioneers in the field like co-founder Kryspin Mirota, can deliver high diagnostic accuracy within a clinician-friendly workflow, all from a company based in a lower-cost engineering hub.
A clinical trial for credibility
In medical technology, especially software intended to inform life-altering clinical decisions, peer-reviewed data is the ultimate currency. Hemolens appears to be playing a long game focused on that evidence. The Cardiolens FFR-CT Pro system is currently being evaluated in a clinical trial listed on an international registry. The study's stated purpose is to measure the platform's diagnostic accuracy, safety, and cost-effectiveness in patients with chronic coronary syndromes [Clinical Trials Registry - ICH GCP, retrieved 2026]. For a European company eyeing both the EU market and global adoption, generating robust clinical data is a non-negotiable step toward CE marking and any future FDA submissions. This methodical focus on validation, rather than premature commercial fanfare, aligns with a prudent regulatory strategy.
The company's operational scale suggests it is well-resourced for this development phase. While its funding history is not public, it has grown to a substantial team. Public records indicate between 101 and 500 employees, with more specific data from PitchBook citing 93 total staff [PitchBook, retrieved 2026] [EMIS, retrieved 2026]. This headcount, significant for a diagnostics startup, points to sustained investment, likely from its backer the Life Science Innovation Fund, and a serious commitment to product development, regulatory affairs, and early commercial infrastructure.
Navigating a field of established competitors
The non-invasive FFR-CT space is not uncontested. Hemolens enters a market where California-based HeartFlow has achieved widespread adoption and regulatory clearance in the U.S. and Europe, setting a high bar for clinical evidence and commercial execution. The competitive set also includes other well-funded players like Elucid and CathWorks, each with distinct technological approaches. For a new entrant, the challenges are multifaceted.
- Clinical validation. HeartFlow's technology is supported by a deep bench of peer-reviewed studies. Hemolens's ongoing trial is a necessary first step, but it will need to demonstrate non-inferiority or superiority in a crowded field to change clinical practice [Clinical Research Trial Listing, retrieved 2026].
- Commercialization muscle. Selling into hospital cardiology and radiology departments requires a sophisticated direct sales or partnership model. Hemolens's recent posting for a Customer Success Specialist hints at building this function, but scaling a commercial operation across Europe and beyond is a different endeavor from R&D [Hemolens, retrieved].
- Regulatory pathway. While the company has announced a partnership with an unnamed "top regulatory partner," the specifics and timeline for achieving CE marking under the EU's new Medical Device Regulation (MDR) remain unclear [Hemolens, retrieved].
Hemolens's most plausible answer to these challenges is its Polish engineering base, which may allow it to develop and iterate its complex CFD software at a lower cost than Silicon Valley peers. This could translate into a more competitive price point for hospitals, a crucial lever in cost-constrained European healthcare systems.
The patient population and the standard of care
The disease state Hemolens is addressing is coronary artery disease (CAD), specifically in patients with chronic coronary syndromes. This is a vast population; CAD remains a leading cause of death worldwide. The current standard of care for diagnosing functionally significant blockages often involves invasive coronary angiography (ICA) with a pressure wire to measure FFR. This procedure, while considered the gold standard, requires a cardiac catheterization lab, carries a small risk of complications, and adds cost. For patients, it can be an anxious and uncomfortable experience. The clinical ideal is to reserve these invasive procedures only for those patients who will definitively benefit from a stent or bypass surgery, avoiding them for everyone else. That is the triage function Hemolens's Cardiolens platform aims to serve: using smart software to analyze a scan the patient may already have, helping cardiologists make more confident, personalized decisions about who truly needs to go to the cath lab.
What to watch in the next 24 months
The immediate future for Hemolens hinges on the outcomes of its clinical research. The publication of its trial results will be the single most important signal of the technology's viability and its potential to gain traction with clinicians. Concurrently, the market will be watching for a CE mark under the EU's MDR, a formal regulatory endorsement that would open the door to commercial sales in Europe. Strategically, the company may also seek to expand its partnership network, potentially linking with large medical imaging OEMs or telehealth platforms to accelerate distribution. For a team that has quietly built to over a hundred people, the next phase is about transitioning from a promising engineering project to a clinically proven, commercially viable tool in the global fight against heart disease.
Sources
- [Hemolens, retrieved 2026] Non-invasive cardiac diagnostics - Hemolens | https://hemolens.com/
- [Clinical Trials Registry - ICH GCP, retrieved 2026] Cardiolens FFR-CT Pro diagnostic accuracy trial listing | https://ichgcp.net/clinical-trials-registry/
- [PitchBook, retrieved 2026] Hemolens employee headcount data | https://pitchbook.com/
- [EMIS, retrieved 2026] Hemolens Diagnostics Sp. z o.o. company profile | https://www.emis.com/
- [Clinical Research Trial Listing, retrieved 2026] Cardiolens FFR-CT Pro trial description | https://clinicaltrials.gov/
- [Hemolens, retrieved] Hemolens Careers page | https://hemolens.com/career/